|
WHAT IS KEYTROPIN?
KeyTropin™
contains a highly advanced, patent pending polypeptide
called HTA-5™ that helps stimulate the body’s own
production of Growth Hormone.
INTRODUCTION
Many scientists now regard aging as both
treatable and reversible. At the core of aging is the
body's progressive inability at self-repair and marked
decrease in hormone levels. The application of this
theory, and the unprecedented growing popularity of
hormonal supplementation, testifies to the success of
hormone replacement therapy as an effective means of
countering the aging process, while restoring the body’s
ability to self-repair.
THEORIES OF AGING
The precise reason why Growth Hormone levels
decrease with advancing age is unknown. However, there are
a number of theories that begin to explain this depression
within the context of an organism’s natural aging
process. The theories are as follows:
Oxidative Stress Theory asserts that the body’s
absorption of oxygen is intricately related to the aging
process. The more food a person or animal consumes, the
more oxygen the body needs to break it down into energy,
and the more rapidly the animal ages due to the creation
of free radicals that impair cell function.
The Genetic Theory of Aging asserts that as genetic
damage accumulates simply as a consequence of living (i.e.
via ongoing cell repair and division); the body’s
overall efficiency decreases, with aging as a consequence.
The Theory of Somatopause (or Cellular Senescence)
asserts that cells are pre-programmed to either die after
a finite number of divisions or simply go dormant. As the
cells lapse into this phase of their cycle, the efficiency
of the organism to maintain its vital functions decreases,
until ultimately the organism itself dies.
The Hormonal Theory of Aging asserts that aging is
linked to a decline in the body’s secretion of a variety
of hormones without losing the ability to respond to these
hormones. This is the principle basis for hormone
replacement therapy with GH.
Comment: Cellular senescence may be caused by the
decreasing length of protective telomeres that are
positioned like protective caps at the ends of chromosomal
DNA. A part of the telomere cap is lost with each
successive cell division, eventually reaching a critical
length at which time cell division stops and the cell ages
and dies. Preservation of these caps preserves cell
viability.
WHAT IS GROWTH
HORMONE?
Mounting science and
clinical evidence has documented the usefulness of Growth
Hormone (GH) as an anti-aging tool and has ensured the
continued relevance of GH in an ongoing exploration of
anti-aging medicine. Central to GH’s value as an
anti-aging tool is its ability to promote cell
regeneration, stimulate tissue repair and energize the
immune system. Since virtually all the complications
related to aging appear to stem from the body’s
progressive inability to repair its cells as it loses
them, GH appears to be center stage in the anti-aging
arena.
Growth Hormone is a 191 amino acid protein chain that is
synthesized and secreted by the pituitary gland found at
the base of the brain. GH enters the bloodstream in
pulses, predominantly at night, and is quickly metabolized
by the liver into insulin-like growth factors IGF-1 and
IGF-2. The natural decrease of GH secretion with age
starts in the mid-twenties and continues as we grow older.
By the age of 60, GH levels are typically reduced to
15-20% of their levels at the age of 25, sometimes even
less.
 |
|
|
|
|
GROWTH HORMONE BENEFITS
People who have used injectable GH have
reported an overall improvement in their general
well-being and vitality, with the following specific
findings:
• Stronger
bones
•
Enhanced immune system
•
Accelerated wound healing / tissue regeneration
•
Decrease in total cholesterol
•
Increase in muscle mass without exercise
•
Loss of body fat without exercise
•
Weight loss
•
Improved blood pressure
•
Younger, more durable skin with fewer wrinkles
•
Increased energy
•
Enhanced sexual performance and libido
•
Increased cardiac output
•
Enhanced exercise performance
•
Improved mood
•
Improved memory
•
Improved sleep pattern
•
Organ regeneration
•
Regrowth of lost hair
INSULIN-LIKE GROWTH FACTORS IGF-1 AND
IGF-2
During the day, GH is released into the
bloodstream in small pulsating bursts, peaking during deep
sleep. Since the longevity of GH in the bloodstream is
very short after its secretion, accurately measuring GH
levels directly can be very cumbersome. Consequently,
measurement of GH levels is typically achieved indirectly,
by measuring for levels of another hormone called
Insulin-like Growth Factor 1 (IGF-1).
IGF-1 is produced by the liver in response to circulating
GH and remains relatively constant throughout the day in
contrast to GH. As such, IGF-1 levels are the standard
means to evaluate how much GH the pituitary is releasing,
especially when looking for a change over time.
The goal of GH replacement therapy by injection for
individuals over 50 is to raise IGF-1 levels within the
range of healthy young adults, which is between 500 to
1500 U/L.
Comment: IGF-1 works directly with GH to promote growth
and regulate metabolism. IGF-2 maintains the health of
nerve tissue and works with GH to stimulate bone marrow
and bone growth.
 |
|
|
|
|
GH RELEASING FACTOR
The principle differences between injectable GH
supplementation and use of a GH releasing factor are
useful to appreciate when considering the available
alternatives in GH technology.
GH injections offer many benefits to the individual, as
just referenced. As with any hormone replacement or
supplementation, however, the converse is also true.
Poorly monitored GH supplementation may be associated with
allergic reactions, carpal tunnel syndrome, irregularities
of bone growth (acromegaly), diabetes and edema
(swelling).
Use of a GH Releasing Factor (GHRF) minimizes possible
complications associated with GH injections while
providing the same benefits. By using a GHRF, IGF-1 levels
increase slowly and plateau at levels far below those
resulting from GH injections. KeyTropin
was designed to be a powerful GHRF that safely offers a
viable alternative to GH injections.
HTA-5™
HTA-5 is a small protein chain that behaves
like GHRF on the pituitary to stimulate the release of GH.
HTA-5 also binds to GH receptors in the liver. The end
result is that HTA-5 generates a measurable IGF-1
response.
|
 |
|
|
|
|
|
CLINICAL TESTING
The clinical trial posed two challenges. The
first was to document the ability of HTA-5 to stand alone
as a new GHRF. The second was to determine if HTA-5 could
be combined with other GHRFs to create a superior result.
(KeyTropin also contains the other releasing factors used
in the clinical trial.) As such, two separate trials were
conducted.
• Trial #1: HTA-5
Ten individuals ranging in age from 30 to 69 years were
given 30 nanograms (or 0.000000030 grams) of HTA5 in the
form of an aerosolized oral spray before bed, over a 30-32
day period.
• Trial #2: HTA-5+
Fifteen individuals ranging in age from 38 to 70 years of
age were given an effervescent tablet to take once daily
over a 25-36 day period that contained 20 ng of HTA-5 in
combination with 1200 mg each of the amino acids lysine
and arginine.
Comment: Previous published experimentation has shown
that the combination of lysine and arginine in the doses
used with Trial #2 is an effective GH releasing factor.
The KeyTropin
clinical trial demonstrated the following:
IGF-1
Summary: All study participants achieved improvements
in IGF-1 levels. Male subjects demonstrated an increase of
up to 50% and female subjects an increase of up to 100%.
Discussion: The principal hormone measured in order to
establish whether there is an increase in growth hormone
secretion is IGF-1. And indeed, clinical research with
HTA-5 alone (Trial #1) confirms that HTA-5 is a bona fide,
stand-alone GH Releasing Factor. Furthermore, it also
appears that HTA-5 in combination with the amino acids
lysine and arginine is capable of increasing IGF-1 levels
in excess of HTA-5 alone. These results confirm that GH
secretion is increased with HTA-5.
In addition, the following observations may be made from
the IGF-1 data shown below: The change in IGF-1
concentrations in the presence of HTA-5 alone or in
combination with amino acids was found to be both age and
sex dependent. A more substantial change in IGF-1
concentrations was noted with advancing age groups,
regardless of sex. A woman’s IGF-1 response to HTA-5
with or without amino acids was calculated to be greater
than a man’s response. This difference in IGF did not
result in significant body mass changes between the sexes.
It should be noted that across all clinical trial
participants, the greatest percent change in IGF-1
concentrations was observed in participants that started
with very low baseline IGF-1 concentrations ( e.g., 21 ng/mL).
Comment: IGF-1 concentrations and total cholesterol levels
were determined by collecting participant blood samples at
the beginning of the studies and at their conclusion.
IGF-1
Cholesterol
Summary: All study participants achieved lower
cholesterol levels; most of which were clinically
significant decreases.
Discussion: The National Cholesterol Education Program (NCEP)
has been advocating that people maintain a low total blood
cholesterol level as a means to minimize the potential for
cardiovascular disease. Current NCEP guidelines recommend
that adult individuals work toward reducing total
cholesterol levels to at least 200 mg/mL as part of a
healthy lifestyle.
The majority of clinical trial participants using
HTA-5 (with or without amino acids) demonstrated a
clinically significant decrease in their total cholesterol
levels over the study period, in the absence of additional
measures. Study results for Trial #2 participants are
presented below.
Cholesterol
Bone Density
Summary: The average increase in bone density for
study participants was 12.6%.
Discussion: The importance of bone density to general
health is very simple. Stated succinctly, an increase in
bone density decreases the chance of fracture and
osteoarthritis. Bone density is a particularly important
issue as the body ages, regardless of sex.
Since an increase in GH levels is known to increase bone
density, the developers of HTA-5 expected that they would
witness an increase in bone density at the conclusion of a
clinical trial using HTA-5. Indeed, the average increase
in bone density for subjects taking HTA5 alone was 6.8%.
The average increase in bone density for subjects taking
HTA5 plus amino acids was 12.6%.
Study results shown below illustrate the bone density
increases measured for men and women in Clinical Trial #2.
Note that neither sex nor age group has a significant
influence on the activity of HTA-5 to affect bone density.
Comment: Radial bone density was measured by
ultrasonographic technique.
Bone Density
Lean Body Mass / Adipose Tissue Mass
Summary: An increase in lean body mass (LBM) and a
decrease in adipose tissue mass (ATM), or body fat, was
recorded for all study participants.
Discussion: One of the basic roles of GH and IGF-1 is in
the regulation of insulin levels, glucose metabolism and
fatty tissue metabolism.
An increase in LBM and a decrease in ATM was recorded for
all study participants in both clinical trials using an
ultrasound-based body composition analysis. The noted
increase in muscle mass and decrease in adipose tissue
mass at the conclusion of the study period was slightly
more than doubled for study participants given HTA-5 with
amino acids. Participants lost an average of 13.2% of
their body weight in conjunction with this change in body
composition – and this was achieved without diet or
exercise. These results are shown below.
Lean Body Mass / Adipose Tissue Mass
Comment: If you would like to obtain the raw data used
in the referenced clinical trials, contact us at info@newuproducts.com.
A second clinical trial on KeyTropin
will begin in July of 2002.
THE TRUTH BEHIND GROWTH HORMONE
CONTAINING ORAL SPRAYS
The inclusion of GH in an oral spray for the
purpose of increasing GH levels in the body raises serious
questions of legitimacy.
GH is a prescription drug and legally cannot be included
in a dietary supplement, no matter how minute the
quantity.
GH taken via an oral spray cannot be absorbed through the
oral mucosa because of its large size of 191 amino acids.
The upper threshold of trans-mucosal absorption for
peptides is around 60 amino acids. Many marketers of
products that purport to contain GH claim to have a
"delivery system" that allows for the transport
of GH via an oral spray, yet there exists no science to
support their claims. If a legitimate technology existed
for the purpose of transporting GH into the body via an
oral spray, the drug companies holding GH patents would
have implemented this technology to offer the public a
means of GH replacement therapy that did not require
injections.
Oral absorption of HTA-5 is based on the peptide’s small
size and its ability to be readily absorbed through the
oral mucosa. The developers of HTA-5 chose to assist the
transmucosal absorption of HTA-5 by including a
non-proprietary and relatively small sugar/protein
transport molecule called a glycosaminoglycan, or GAG
molecule, into the formulation. This transport molecule
increases the transmucosal absorption of HTA-5 and also
helps to stabilize HTA-5 in the formulation. HTA-5 was
attached to GAG molecules in all clinical trials performed
to date.
In addition to GH’s large size as a prohibitive factor
for an oral spray formulation, it should also be
understood that GH in liquid form is extremely unstable.
Consequently, although there may be some degree of
concentration of GH placed in solution at the time of
manufacture, the GH will be rapidly destroyed and final
levels of GH by the time the product gets into the hands
of the end consumer will be very low, if existent at all.
At this time, there is no sure fire technology available
to stabilize GH in solution, especially in the type of
solutions being used in these products. The only means of
maintaining GH in solution to date has been to
reconstitute GH in a solution that contains a
scientifically precise environment (bacteriostatic water)
immediately before injection. The GH then only remains
stable for a matter of days.
The amount of GH alleged to be contained in most GH-containing
oral sprays is too insignificant to produce any notable GH-related
benefit, even if the GH were viably active and could be
delivered to the bloodstream. The amount of GH claimed to
be contained in a typical serving of GH-containing oral
sprays represents less than 001% of the amount of GH found
in a typical injection taken for GH replacement therapy.
When approached by someone trying to sell you a product
that purports to contain GH, simply say to that person,
"Show me the science behind your product."
KEYTROPIN
VERSUS GROWTH HORMONE INJECTIONS
KeyTropin
with HTA-5 is ideal for those individuals whose objective
is to benefit from an increase in their body’s own
release of GH without the hassles of GH injections. In
particular:
KeyTropin
use will not suppress the body’s natural cyclical
release of GH, as is commonly the case with GH injections.
Consequently, you may start and stop the use of KeyTropin
without risk.
KeyTropin
users can comfortably use HTA-5 in the absence of
physician supervision because HTA-5 does not expose the
body to the pharmacologic concentrations of GH commonly
used with GH injections.
MAXIMIZING YOUR GROWTH HORMONE LEVELS
The decrease in GH synthesis and secretion
during a lifetime is a natural phenomenon consistent with
the aging process. The following is a list of simple and
effective techniques that increase GH secretion naturally
and with varying degrees of effort.
Exercise and strength training. Weight training that uses
leg, chest and back muscles has been shown to be the best
natural stimulant for invigorating the body and
stimulating GH secretion.
Raising blood sugar levels decreases GH secretion. Avoid
eating before bedtime and minimize your intake of simple
sugars found in soda, fruit juice, candy and other snack
products.
Increase your dietary protein intake from poultry, fish,
dairy products, and soy and meat products. Protein intake
is fundamental to tissue regeneration
KEYTROPIN
PRODUCTS
KeyTropin is available as an oral spray or in
tablet form.
KeyTropin
Oral Spray
The oral spray provides HTA-5™ in smaller doses more
than once daily.
KeyTropin
Tablets
The tablet provides a
higher dose of HTA-5 taken once before bedtime, yielding a
more pronounced effect at improving deep, restful sleep.
LABEL INFORMATION
KeyTropin
Oral Spray
Ingredients: HTA-5™ polypeptide containing the
following amino acids: Leucine, Proline, Lysine,
Glutamine, Aspartic Acid, Metionin, Alanine
Other Ingredients:
Deionized Water, L-Lysine, L- Arginine, L-Ornithine,
L-Glutamine, Melatonin, Pyridoxine HCl, Trace Minerals
[Calcium, Iron and Sulfate], Potassium Sorbate, Sodium
Benzoate, Benzyl Alcohol
This product does not contain
Growth Hormone.
Suggested Use: Take 2-3
sprays in the mouth under the tongue 2-3 times daily.
Precautions:
• This product is not
recommended for individuals under the age of 21.
• Do not use if pregnant or
nursing without first consulting a physician.
• Keep out of reach of
children.
• Do not store at extreme
temperatures.
• Mild, transient headache
may occur in some individuals during initial use.
Precautions:
• This product is not
recommended for individuals under the age of 21.
• Do not use if pregnant or
nursing without first consulting a physician.
• Keep out of reach of
children.
• Do not store at extreme
temperatures. |
